RxDoctor Payments DataLook up a doctor →

Karen Smith

Family · Springfield, PANPI 1285186809

Payments from drug & device makers

$15,978in general payments, 2019–2025

Across 578 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • GSK$903
  • Johnson & Johnson$763
  • plus $8K from 48 others

What the payments were for

  • Food & beverage$15,912100%
  • Education$660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,978 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,312
Medicare patients
185
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HetliozTasimelteon12$274,281
EliquisApixaban146$91,504
RexultiBrexpiprazole23$44,575
OzempicSemaglutide34$40,468
JardianceEmpagliflozin55$36,491
RybelsusSemaglutide26$24,177
Rufinamide13$22,021
TrulicityDulaglutide20$19,423
XareltoRivaroxaban33$17,156
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,832
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,092
Breo ElliptaFluticasone/Vilanterol13$8,502
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,118
MyrbetriqMirabegron16$7,676
Mesalamine11$6,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$753$91,504146 claims
Novo NordiskOzempic, Rybelsus$1,721$64,64560 claims
Otsuka America Pharmaceutical, Inc.Rexulti$221$44,57523 claims
Boehringer IngelheimJardiance$718$36,49155 claims
GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta$903$26,71246 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$1,305$20,48046 claims
Lilly USA, LLCTrulicity$1,164$19,42320 claims
Johnson & JohnsonXarelto$763$17,15633 claims
Astellas Pharma US IncMyrbetriq$309$7,67616 claims
Sumitomo Pharma America, Inc.Gemtesa$30$5,47811 claims
Almatica Pharma LLCSertraline Hcl$16$2,603246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Springfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →